Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Pharmaceutical
Isabel Torres, global head for access to medicine at Japanese pharma major Takeda Pharmaceutical, tells The Pharma Letter about its Access to Medicine (AtM) strategy. 17 February 2017
Pharmaceutical
The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List - the latter includes countries that are alleged violators of US patent laws - Pharmaceutical Research and Manufacturers of America (PhRMA), in its submission, has requested the USTR to continue to keep India on the Priority Watch List in the 2017 Special 301 Report, reports The Pharma Letter’s India correspondent. 16 February 2017
Pharmaceutical
According to Public Health England’s Annual Flu Report, there have been more than three million deaths in the UK since 2006 from flu. In an expert view piece, Nick Hawkins, managing director for EMEA at global mass notifications software provider Everbridge, shows how mass notification solutions can be used to stop the death toll rising. 15 February 2017
Pharmaceutical
In the newly-released “opinions on policies for drug manufacturing and distribution” by the State Council, which holds the highest power in China, the focus is made clear – keep improving drug quality and cutting drug prices, reports The Pharma Letter’s local correspondent Wang Fangqing. 15 February 2017
Pharmaceutical
A pharma veteran has switched from one of the industry’s giants to another to lead its UK pharmaceuticals business. 15 February 2017
Biosimilars
Dr Nicola Davies explores how pharma companies can secure the future of biobetters in the presence of biosimilars and increased payer scrutiny on high prices. 14 February 2017
Pharmaceutical
There are about 40 foreign pharma companies with integrated operations in Japan, each headed by a president/representative director, says P Reed Maurer, long time pharma industry watcher who is president of International Alliances Limited. 13 February 2017
Pharmaceutical
Christine Lind has been appointed as the new chief executive of Swedish drugmaker Medivir. 9 February 2017
Biotechnology
Oxford BioTherapeutics (OBT) has added two new names to a board now boasting significant experience in developing immuno-oncology and antibody-based therapies. 9 February 2017
Pharmaceutical
Carole Longson spent eight years developing novel pharmaceuticals at GlaxoSmithKline, before crossing the floor to join the UK’s national health watchdog, the National Centre for Health and Care Excellence (NICE). The Pharma Letter speaks with her about the importance of cost-effectiveness, the value of the revised Cancer Drugs Fund, the growing role played by real-world evidence, and her hopes for a positive decision on Kadcyla (trastuzumab emtansine). 8 February 2017
Pharmaceutical
A new policy released by China’s State Council, which holds the highest power in the country, aims to largely reduce vaccine injuries in the nation, reports The Pharma Letter’s local correspondent Wang Fangqing. 8 February 2017
Biotechnology
Danish biotech firm Genmab has a third member of its executive team. 8 February 2017
Pharmaceutical
With opioid abuse in the USA now a major crisis and the use of certain non-opioids in combination with these drugs a major potential risk, Thomas W. Frederickson, lead author of the Society of Hospital Medicine guide Reducing Adverse Drug Events Related to Opioids (RADEO), writes about reducing the risk of death and the related US Food and Drug Administration (FDA) warnings in an Expert View piece. 8 February 2017
Pharmaceutical
French drugmaker Ipsen has added years of big pharma experience to its executive and research and development (R&D) leadership teams. 7 February 2017
Biotechnology
France-based Nanobiotix has appointed Alain Dostie as its chief operating officer. 7 February 2017
Pharmaceutical
Our most detailed article yet on what we know, and do not yet know, about how the new US President could affect pharma. 6 February 2017
Pharmaceutical
Drug prices in Russia may increase by 20%-25% this year, due to the implementation of the latest state initiative for the introduction of mandatory QR-labelling on drugs in the local market. 3 February 2017
Pharmaceutical
In an expert view piece, Jim Sykes, sector managing director for pharmaceutical and life sciences at global talent acquisition and management firm, Alexander Mann Solutions, considers current risks of losing skilled personnel and how these can be addressed. 2 February 2017
Pharmaceutical
French pharma group Ipsen’s acquisition of the oncology assets of Merrimack Pharmaceuticals (Nasdaq: MACK), which was announced in the first working week of 2017, was potentially evidence not just of a busy year to come in mergers and acquisitions (M&A) for the pharma sector. 1 February 2017
Pharmaceutical
Sanofi today announces the appointment of Hugo Fry as general manager for the UK and general manager Sanofi Pasteur for the UK & Ireland, and Dr Hubert Bland as UK medical chair and medical head of diabetes and cardiovascular for the UK & Ireland. 1 February 2017
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze